JB Pharma Q3 FY24 Net Profit Soars 26% to Rs. 134 Crore

JB Chemicals and Pharmaceuticals Ltd (JB Pharma), one of India's fastest-growing pharmaceutical companies, announced its financial results for the quarter that ended December 31, 2023.JB Pharma reported a profit of Rs. 845 crore in Q3 FY24, registering a growth of 7% from Rs. 793 million in the third quarter of 2023.

Operating EBITDA (earnings before interest, depreciation, amortization and taxes) improved by 22% to Rs. 235 crore in Q3 FY24 compared to Rs. 19.3 billion in the third quarter of fiscal 2023. Profit after tax rose 26% to Rs. 134 million in 3Q 2024 vs. $160 million in the third quarter of 2023. Regarding the financial results, Nikhil Chopra, CEO and Managing Director of JB Pharma, said, “Our focus is to grow our housing business before the market continues, "Reflected in our third quarter results. Companies also appeared in this quarter. As of CY 2023, we are the fastest-growing company in IPM among 25 pharmaceutical companies.

We are excited about our recent entry into the ophthalmology industry, which brings some of the leading brands, the best of everything, to the JB family. There is a lot of potential in the ophthalmology sector as we expect this market to grow among young people and continue the growth of IPM.In the international industry, the pharmaceutical business is a year.

Our order book for our CDMO business will look good in the coming quarters. "Our approach to incremental fund development is progressing well and has a positive impact on our export brands business."During the nine months of the financial year 2023-24, the company recorded revenue of Rs. 2,622 crore compared to Rs. It registered a growth of 10% to 238.7 billion dollars. Operating EBITDA increased by 25% to Rs. 729 crore compared to Rs. 58,400 million. Profit after tax rose 32% to Rs. 42.6 crore for Rs. 322 crore in 9M FY23.